Classical molecular markers with clinical implications such as MGMT promoter methylation, 1p 19q codeletion, and IDH1 mutations are known favorable prognostic markers in gliomas, with MGMT promoter methylation being the only potential predictive marker for alkylating chemotherapy in GBM. Here, MGMT is linked to glioblastoma.